StockSaints Logo 

Pfizer Earnings Preview For Tuesday

Pfizer Inc. Company Logo Image

Pfizer, Inc. (PFE)

Background: Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide.

 

Pfizer is forecast to record lower second-quarter earnings before the market opens on July 30, 2013.

The consensus estimate is currently 56 cents a share, a drop of 6 cents (9.7%) from 62 cents during the equivalent quarter last year. Analysts are estimating as low as 52 cents per share, up to the most optimistic estimate of 61 cents per share.

Investors are receiving 96 cents in dividends for a yield of 3.3%.

Over half the analysts covering Pfizer rate it as a buy or strong buy. 13 of the 19 analysts covering the company give a buy recommendation. 4 analysts rate it a hold, and 2 recommend selling.

 

4 out of 19 analysts now rate Pfizer a strong buy down from 5 analysts a month ago. Compared to three months ago, fewer analysts are rating this company as a strong buy. Analysts overall have called this one correctly. In the last 12 months, the shares have accelerated higher. The one year return is 25%. The average analyst current target price for Pfizer is $31.06.
 

Presently, based on the float the short interest is unimportant and not a worry. The small amount of short interest is 2.4%.

 

 

(PFE)

(MRK)

(NVS)

(SNY)

Strong Buy

4

4

2

2

Moderate Buy

9

6

0

1

Hold

4

7

3

1

Moderate Sell Ratings

1

0

0

0

Strong Sell Ratings

1

1

0

0

Avg Analyst Price Target

$31.06

$51.73

$76.79

$61.57

Revenue

$51.94 billion

$45.03 billion

$57.56 billion

$46.50 billion

Est Low EPS

0.52

0.80

1.28

N/A

Est High EPS

0.61

0.84

1.34

N/A

1 Year Stock Price Change

22.49%

6.81%

24.04%

30.56%

 

Rate this article: 
Average: 5 (1 vote)
Stock Tickers: PFE MRK NVS SNY Author Disclosure: n/a
Tickers: